Patents by Inventor Tania GONZÁLEZ GARCÍA

Tania GONZÁLEZ GARCÍA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11642309
    Abstract: The invention relates to an aqueous pharmaceutical composition comprising: a) bilastine or a pharmaceutically acceptable salt or solvate thereof, b) mometasone, or a pharmaceutically acceptable derivative thereof, c) a suspending agent, and d) 2-hydroxypropyl-?-cyclodextrin; wherein the pH of the aqueous pharmaceutical composition is between 3.5 and 5.5, and wherein the content of 2-hydroxypropyl-?-cyclodextrin is less than 8.5% by weight. The invention also relates to said compositions for use in the treatment and/or prevention of a disorder or disease susceptible to amelioration by antagonism of H1 histamine receptor and/or of a corticosteroid-responsive disease through nasal administration. The invention also relates to a process for preparing the aqueous pharmaceutical composition above mentioned.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: May 9, 2023
    Assignee: FAES FARMA, S.A.
    Inventors: Gonzalo Hernández Herrero, Ana Gonzalo Gorostiza, Neftalí García Domínguez, Arturo Zazpe Arce, Pablo Morán Poladura, Tania González García
  • Patent number: 11591280
    Abstract: The invention relates to new intermediates in the synthesis of Eldecalcitol and to processes for the preparation of said intermediates and of Eldecalcitol.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: February 28, 2023
    Inventors: Gonzalo Hernández Herrero, Neftalí García Domínguez, Tatiana María Suárez Cortés, Tania González García, Generosa Gómez Pácios, Yagamare Fall Diop, Hugo Santalla García, Fátima Garrido Fernández
  • Publication number: 20220204433
    Abstract: The invention relates to new intermediates in the synthesis of Eldecalcitol and to processes for the preparation of said intermediates and of Eldecalcitol.
    Type: Application
    Filed: May 12, 2020
    Publication date: June 30, 2022
    Inventors: Gonzalo HERNÁNDEZ HERRERO, Neftalí GARCÍA DOMCÍNGUEZ, Tatiana María SUÁREZ CORTÉS, Tania GONZÁLEZ GARCÍA, Generosa GÓMEZ PÁCIOS, Yagamare FALL DIOP, Hugo SANTALALLA GARCÍA, Fátima GARRIDO FERNÁNDEZ
  • Patent number: 11370742
    Abstract: The invention relates to a process for preparing a compound of (III) wherein X is a leaving group; and R1 is C1-C6 alkyl; which comprises oxidative rearrangement of a compound of formula (II) or a solvate thereof Compounds of formula (III) are key intermediates in the synthesis of Bilastine.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: June 28, 2022
    Inventors: Gonzalo Hernández Herrero, Neftalí García Domínguez, Pablo Morán Poladura, Tania González García, Álvaro Ganza González, Paloma Tato Cerdeiras
  • Publication number: 20210300856
    Abstract: The invention relates to a process for preparing a compound of (III) wherein X is a leaving group; and R1 is C1-C6 alkyl; which comprises oxidative rearrangement of a compound of formula (II) or a solvate thereof Compounds of formula (III) are key intermediates in the synthesis of Bilastine.
    Type: Application
    Filed: July 23, 2019
    Publication date: September 30, 2021
    Inventors: Gonzalo HERNÁNDEZ HERRERO, Neftalí GARCÍA DOMÍNGUEZ, Pablo MORÁN POLADURA, Tania GONZÁLEZ GARCÍA, Álvaro GANZA GONZÁLEZ, Paloma TATO CERDEIRAS
  • Publication number: 20210186869
    Abstract: The invention relates to an aqueous pharmaceutical composition comprising: a) bilastine or a pharmaceutically acceptable salt or solvate thereof, b) mometasone, or a pharmaceutically acceptable derivative thereof, c) a suspending agent, and d) 2-hydroxypropyl-?-cyclodextrin; wherein the pH of the aqueous pharmaceutical composition is between 3.5 and 5.5, and wherein the content of 2-hydroxypropyl-?-cyclodextrin is less than 8.5% by weight. The invention also relates to said compositions for use in the treatment and/or prevention of a disorder or disease susceptible to amelioration by antagonism of H1 histamine receptor and/or of a corticosteroid-responsive disease through nasal administration. The invention also relates to a process for preparing the aqueous pharmaceutical composition above mentioned.
    Type: Application
    Filed: October 15, 2018
    Publication date: June 24, 2021
    Applicant: FAES FARMA, S.A.
    Inventors: Gonzalo HERNÁNDEZ HERRERO, Ana GONZALO GOROSTIZA, Neftalí GARCÍA DOMÍNGUEZ, Arturo ZAZPE ARCE, Pablo MORÁN POLADURA, Tania GONZÁLEZ GARCÍA
  • Publication number: 20210128544
    Abstract: The invention relates to an aqueous ophthalmic pharmaceutical composition comprising: a) at least 0.4% w/v of bilastine, of formula or a pharmaceutically acceptable salt or solvate thereof, wherein the bilastine salt or solvate thereof is completely dissolved in the pharmaceutical composition; b) at least one ?-cyclodextrin; and c) at least one pharmaceutically acceptable water-soluble gelling agent; and wherein the pH is comprised between 4 and 9. and its use in the treatment and/or prevention of conditions mediated by H1 histamine receptor, such as allergic disorders or diseases. The invention relates to the treatment and/or prevention of allergic conjunctivitis.
    Type: Application
    Filed: January 9, 2019
    Publication date: May 6, 2021
    Inventors: Gonzalo HERNÁNDEZ HERRERO, Ana GONZALO GOROSTIZA, Pablo MORAN POLADURA, Arturo ZAZPE ARCE, Nieves FERNANDEZ HERNANDO, Tania GONZALEZ GARCIA, Paloma TATO CERDEIRAS, Francisco Javier OTERO ESPINAR, Anxo FERNANDEZ FERREIRO, Victoria DIAZ TOME